Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
18.4.2023 11:00:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005217/en/
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health (Photo: Business Wire)
BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source, and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine.
“The new strategic collaboration, highlights Ferring’s continued commitment to invest in early-stage innovation in this area, and we look forward to strengthening our collaboration with BII to accelerate new solutions for patients,” says Armin Metzger, Executive Vice President and Chief Science Officer at Ferring.
The strategic collaboration builds on Ferring’s engagement with BII’s Women’s Health Initiative through Ferring’s membership on the BII Women’s Health Innovation Panel. Women’s health is underserved as only 1% of global healthcare research funding is invested in female-specific conditions beyond oncology.1 The collaboration aims to bridge the gap by supporting early-stage innovation and will leverage BII’s proven expertise in translational science incubation, together with Ferring’s expertise in early-stage development and reproductive medicine.
“Combining BII’s already proven incubation expertise with the industrial expertise and deep insights that Ferring has within women’s health forms a very strong basis for supporting and accelerating our mission of getting more solutions on the market that address the high unmet needs of 50% of the world’s population. We are pleased to collaborate even closer with Ferring to make it happen,” says Trine Bartholdy, Chief Innovation Officer at the BioInnovation Institute.
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, Facebook, Twitter and YouTube.
The BioInnovation Institute Foundation:
At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to EUR 3 million per project and EUR 1,8 million per start-up. With our expertise, network, funding, and infrastructure, we empower start-ups to succeed and believe in the transformative power of life science innovation. Read more on www.bioinnovationinstitute.com.
1 McKinsey & Company. Unlocking opportunities in women’s healthcare. 2022. Available at: https://www.mckinsey.com/industries/healthcare/our-insights/unlocking-opportunities-in-womens-healthcare [Last accessed April 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005217/en/
Contact information
For more information, please contact:
Ferring Pharmaceuticals
Björn Lindström
Director, Corporate Communications & Public Affairs
+45 28 78 78 62
Bjoern.lindstroem@ferring.com
BioInnovation Institute
Casper Linnemann
Head of Communication
+45 4172 7994
cli@bii.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Demonstrates Entanglement Across a Complete 54-Qubit Processor, Bringing Full-Chip Performance to Cloud Users29.10.2026 09:00:00 EET | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced that its cloud-accessible IQM Emerald system has fully entangled all 54 qubits on the chip simultaneously, a result that shows the system’s computational quality holds up when every qubit is put to work at once. IQM’s cloud customers now have access to that same full-chip performance, so their computations can draw on the entire processor rather than a fraction of it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029191153/en/ IQM measured a fidelity of 0.515 at 40 qubits without readout error mitigation (REM) and 0.516 at the full 54 qubits with REM applied, both above the classical threshold of 0.500 that separates genuine entanglement from noise. These results rank among the strongest reported for any commercially available quantum computer, giving customers access to state-of-the-art, high-quality processors. U
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones29.10.2026 08:36:00 EET | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda’s focus remains on execution against the first horizon of its growth strategy: successfully launching three new medicines, advancing its late-stage pipeline, ensuring resilience of core in-line brands and executing its transformation program. FY2026 First-Half Highlights Revenue increased by 8.4% versus the prior period on an actual exchange rates (AER) basis and decreased by 1.0% at constant exchange rates (CER). Core Operating Profit increased by 11.2% on an AER basis, and increased by 0.7% on a CER basis, supported by enterprise-wide transformation, which is helping fund growth investments. Reported Operat
AB InBev Reports Third Quarter 2026 Results29.10.2026 08:01:00 EET | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028546637/en/ Regulated and inside information1 “Delivering solid growth today while investing for tomorrow - our portfolio of megabrands and mega platforms continues to win with consumers, and our performance this quarter reflects the strength of our diversified footprint, best-in-class capabilities and consistent execution of our strategy. Thank you to our colleagues around the world for their commitment and dedication as we continue to compound growth and create long-term value.” – Michel Doukeris, CEO, AB InBev Revenue +4.9% Revenue increased by 4.9% in 3Q26 with revenue per hl growth of 4.2% and by 5.4% in 9M26 with revenue per hl growth of 4.3%. Reported revenue increased by 9.1% in 3Q26 to 16 512 million USD and by 10.7% in 9M26 to 48 439 million USD, positively impacted by currency translation. 7.7% in
EIG and Acwa Announce Plenum Power, a Strategic Partnership to Invest in U.S. Power Infrastructure29.10.2026 07:00:00 EET | Press release
EIG, a leading institutional investor in the global energy and infrastructure sectors, and Saudi-listed Acwa, one of the world's largest independent power producers, today announced that they have entered into definitive agreements to establish Plenum Power, a strategic partnership focused on investment opportunities in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028377569/en/ Dr. Samir J. Serhan, Chief Executive Officer of Acwa (left), and R. Blair Thomas, Chief Executive Officer of EIG (right) Building on an established relationship that includes prior collaboration on projects in the Middle East, EIG and Acwa are now partnering to pursue opportunities in the U.S. power sector through Plenum Power. The parties intend for Plenum Power to target a launch with an initial equity commitment of approximately $4 billion. The partnership combines Acwa's global capabilities in developing, financing, constru
Murata Launches World’s Smallest RF / Microwave Coaxial Connectors with a Switch, Cutting PCB Mounting Area by Approximately 40%29.10.2026 04:00:00 EET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of the SWL series MM8330-2600RJ5 and MM8330-2600RK20, the world’s smallest RF / microwave coaxial connectors with a switch*. Measuring just 1.0 mm × 1.0 mm × 0.55 mm, the new connectors reduce PCB mounting area by approximately 40% compared with Murata’s previous SWJ series. When used with dedicated probes, the SWL series reduces its PCB footprint, including the keep-out area, by approximately 60% compared with Murata’s previous SWJ series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028261665/en/ [Murata Manufacturing Co., Ltd.] RF / microwave coaxial connectors with a switch As wireless devices incorporate more functionality, rising component counts are placing increasing pressure on limited PCB space. RF test connectors require not only mounting area for the connector itself, but also sufficient clearance around the component
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom